B. Riley Analysts Reduce Earnings Estimates for Cytokinetics

Cytokinetics, Incorporated (NASDAQ:CYTK) – Equities researchers at B. Riley reduced their FY2025 EPS estimates for shares of Cytokinetics in a research note issued on Wednesday, March 5th. B. Riley analyst M. Mamtani now forecasts that the biopharmaceutical company will post earnings of ($5.65) per share for the year, down from their previous forecast of ($5.30). The consensus estimate for Cytokinetics’ current full-year earnings is ($5.24) per share. B. Riley also issued estimates for Cytokinetics’ FY2026 earnings at ($5.58) EPS, FY2027 earnings at ($4.63) EPS and FY2028 earnings at ($2.37) EPS.

Cytokinetics (NASDAQ:CYTK) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($1.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.29) by $0.03. The business had revenue of $16.93 million for the quarter, compared to analyst estimates of $14.26 million.

CYTK has been the topic of several other reports. Evercore ISI raised shares of Cytokinetics to a “strong-buy” rating in a report on Friday, February 7th. Needham & Company LLC reissued a “buy” rating and issued a $72.00 price target on shares of Cytokinetics in a research report on Thursday, February 6th. Stifel Nicolaus started coverage on Cytokinetics in a report on Wednesday, January 22nd. They issued a “buy” rating and a $80.00 price objective on the stock. HC Wainwright reiterated a “buy” rating and set a $120.00 price target on shares of Cytokinetics in a report on Friday, February 28th. Finally, Citigroup initiated coverage on Cytokinetics in a research report on Friday, February 7th. They issued a “buy” rating and a $86.00 target price for the company. Two research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $82.00.

Cytokinetics Price Performance

Cytokinetics stock opened at $43.27 on Friday. Cytokinetics has a 12-month low of $40.53 and a 12-month high of $75.71. The stock has a market capitalization of $5.12 billion, a P/E ratio of -8.04 and a beta of 0.95. The firm’s 50-day moving average is $46.91 and its two-hundred day moving average is $50.98. The company has a debt-to-equity ratio of 5.93, a current ratio of 9.28 and a quick ratio of 9.28.

Institutional Inflows and Outflows

Several hedge funds have recently made changes to their positions in CYTK. Vanguard Group Inc. boosted its stake in Cytokinetics by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 11,915,821 shares of the biopharmaceutical company’s stock valued at $560,520,000 after buying an additional 154,216 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its stake in shares of Cytokinetics by 11.0% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 10,752,123 shares of the biopharmaceutical company’s stock worth $505,780,000 after buying an additional 1,062,136 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Cytokinetics by 4.0% during the third quarter. Geode Capital Management LLC now owns 2,848,584 shares of the biopharmaceutical company’s stock worth $150,433,000 after buying an additional 109,938 shares during the last quarter. Deep Track Capital LP raised its stake in shares of Cytokinetics by 296.9% in the fourth quarter. Deep Track Capital LP now owns 2,500,000 shares of the biopharmaceutical company’s stock valued at $117,600,000 after purchasing an additional 1,870,094 shares in the last quarter. Finally, Vestal Point Capital LP raised its stake in Cytokinetics by 56.7% during the fourth quarter. Vestal Point Capital LP now owns 2,350,000 shares of the biopharmaceutical company’s stock worth $110,544,000 after acquiring an additional 850,000 shares in the last quarter.

Insider Activity at Cytokinetics

In related news, EVP Fady Ibraham Malik sold 7,300 shares of Cytokinetics stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $50.64, for a total value of $369,672.00. Following the transaction, the executive vice president now directly owns 116,071 shares in the company, valued at $5,877,835.44. This trade represents a 5.92 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director John T. Henderson sold 1,780 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $50.42, for a total value of $89,747.60. Following the completion of the sale, the director now owns 38,461 shares in the company, valued at approximately $1,939,203.62. This represents a 4.42 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 17,822 shares of company stock worth $874,048. 3.40% of the stock is currently owned by company insiders.

About Cytokinetics

Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility.